MicroRNAs (miRNAs), the smallest genetic material known, offer tremendous promise as biomarkers for early detection of diseases—from cancer and cardiovascular disease to metabolic, neurodegenerative, and infectious diseases. Mirxes offers advanced miRNA profiling capabilities to power your discovery and translational research.

While miRNAs play an essential role in regulating gene expression, they are difficult to detect accurately due to their small size. Our class-leading ID3EAL™ RT-qPCR technology overcomes this challenge, accurately detecting and quantifying miRNAs. Mirxes has also assembled the world’s largest clinical mRNA database, providing valuable insight for research.

Broad Applications

miRNA profiling has a wide range of potential applications, including diagnostic and prognostic tests,1,2,5,6 therapy selection7, treatment monitoring1, disease stratification4, and companion diagnostics3.

Unique Approach

Our novel three primer approach yields high sensitivity, specificity, and robustness, minimizing generation of non-specific cDNA.

Comprehensive Services

End-to-end, sample-to-report service encompassing RNA isolation, library prep, and bioinformatics.

Exceptional Performance

Our methodology offers efficient discrimination among homologs, consistent performance for difficult templates, and excellent reproducibility.

Let’s create an miRNA profiling solution for you

Contact Us

Demonstrated Highly Sensitive Detection

In a 2021 cross-platform evaluation study conducted in collaboration with Merck Sharp and Dohme (MSD), our technology detected the highest number of miRNAs above the lowest limit of quantification8. The study was done with minimal sample input with only 100-200µl of serum/plasma or 50-100ng RNA.

Read our Biomarker Discovery Solution Brief

ObjectiveDiscoveryDiscoveryDiscoveryValidation
ServiceSmall RNA SequencingID3EAL
Panel Profiling		ID3EAL
Premium 700		Customized panels
AdvantagesHigh coverageHigh sensitivityHighly controlled High sensitivityHigh sensitivity
TechnologyNGSRT-qPCRRT-qPCRRT-qPCR
No. of TargetsGenome-wide376700As requested
QuantificationAbsolute
(by read counts)		RelativeAbsolute
(by reference standards)		As requested
RNA Input Requirement> 3 μg
(> 20 μL, > 50ng/μL)		100 ng
(> 50 ng/μL)		50 ng
(> 50 ng/μL)		100 ng
(> 50 ng/μL)

References:

  1. Kahraman M. et al. MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer. Scientific Reports 2018; Vol.8, Article 11584.
  2. Reis P. et al. MicroRNAs as liquid biopsy biomarkers for early detection in lung cancer. Journal of Thoracic Oncology 2018; 13(10):S785-S786.
  3. Ji J. et al. Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in heptacocellular carcinoma. International Journal of Biological Sciences 2013; 9(3):303-12
  4. Fadaka AO. et al. Biomarkers for stratification in colorectal cancer: microRNAs. Cancer Control 2019; 26(1):1-11
  5. Wang J. et al. MicroRNA as biomarkers and diagnostics. Journal of Cellular Physiology 2015; 231(2):25-30.
  6. Yang J. et al. Expression analysis of microRNA as prognostic biomarkers in colorectal cancer. Oncotarget 2016; 8(32):52403-12.
  7. Chan HW. et al. A pilot study on microRNA profile in tear fluid to predict response to anti-VEGF treatments for diabetic macular edema. Journal of Clinical Medicine 2020; 9(9):2920
  8. Hong LZ, Zhou L, Zou R, Khoo CM, Chew ALS, Chin CL, Shih SJ. Systematic evaluation of multiple qPCR platforms, NanoString and miRNA-Seq for microRNA biomarker discovery in human biofluids. Sci Rep. 2021 Feb 24;11(1):4435. doi: 10.1038/s41598-021-83365-z. PMID: 33627690; PMCID: PMC7904811.